FSSAI opens three cases against Nestlé India over NAN and Lactogen claims
FSSAI has initiated three adjudication cases against Nestlé India over alleged non-compliant promotional claims for NAN Excella Pro Stage 1 and Lactogen Pro 1, alongside a follow-up formula quality issue involving biotin. No final penalty has been announced.
What happened
FSSAI has initiated three adjudication cases against Nestle India over alleged non-compliant promotional claims for NAN Excella Pro Stage 1 and Lactogen Pro 1,
Key facts
- Three separate adjudication cases
- 5 HMOs
What changed
FSSAI has initiated three adjudication cases against Nestle India over alleged non-compliant promotional claims for NAN Excella Pro Stage 1 and Lactogen Pro 1, and below-standard biotin in a follow-up formula. No final penalty has been announced.
Why this matters
The three FSSAI cases create a near-term reputational and regulatory overhang for Nestlé India’s infant-nutrition portfolio, although no final penalty has been announced.
What to watch
- FSSAI adjudication notices, hearing dates, findings, penalty orders, or mandated corrective actions.
- Any product recall, stop-sale direction, batch-specific alert, or clarification related to biotin quality.
- Changes in availability, pricing, promotions, or retailer placement for NAN Excella Pro Stage 1 and Lactogen Pro 1.
- Nestlé India disclosures on provisions, legal contingencies, sales impact, or changes to infant-nutrition marketing practices.
- Expansion of FSSAI inquiries to other Nestlé infant-nutrition products or competing formula brands.